Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Kardigan, Inc.

NASDAQ: KARD · Life Sciences · 4 alerts · CIK 2123613

Share price
$12.85Close, Nov 16
Market cap
$1.2B
Shares outstanding
93.6MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Kardigan, Inc. filings on SEC EDGAR ↗

7:11 AM ET 10-Q
Financial Results

Kardigan Q3 2026 Results: Net Loss of $58.6M, Loss Narrows

Kardigan, Inc. is a clinical-stage biopharmaceutical company focusing on cardiovascular diseases with lead candidates Danicamtiv, Ataciguat, and Tonlamarsen. As of November 2026, the company is an emerging growth company with 93,597,398 shares of common stock outstanding and continues to anticipate significant financial losses as it funds its clinical trials and Prolaio platform development.

Key figure
Net loss $58.6M
7:02 AM ET 8-K
Financial Results

Kardigan Financial Results

Kardigan, Inc. reported third quarter 2026 financial results, ending the period with $591.4 million in cash to fund operations through 2027. The company achieved significant clinical milestones, including completing enrollment in the Phase 2b portion of its danicamtiv KINSHIP-DCM trial and the Phase 2b KATALYST-AV trial for ataciguat. Topline data for the danicamtiv trial is expected in the second quarter of 2027.

Term
Q3 2026

“We made meaningful progress this quarter in advancing our portfolio of late-stage cardiovascular programs for people who urgently need better treatment options. Completing enrollment in the Phase 2b portion of our Phase 2b/3 adaptive KINSHIP-DCM trial is a significant milestone for danicamtiv and for people with genetic dilated cardiomyopathy.”

Tassos Gianakakos, co-founder, chief executive officer and board chair

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.